+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Liver Diseases Therapeutics Market by Disease Type, Therapy Type, Route Of Administration, Drug Class, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4904957
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Liver Diseases Therapeutics Market is experiencing rapid evolution, with emerging technologies, evolving regulatory expectations, and complex global dynamics influencing treatment development and commercialization. Senior decision-makers must remain attuned to these fundamental shifts to maintain a competitive edge and shape effective strategic responses.

Market Snapshot: Liver Diseases Therapeutics Market

The Liver Diseases Therapeutics Market grew from USD 18.76 billion in 2024 to USD 20.26 billion in 2025. It is expected to continue growing at a CAGR of 8.13%, reaching USD 30.00 billion by 2030. This momentum is being fueled by a combination of breakthrough scientific developments and the urgent need for more targeted, effective, and accessible therapies across all major global regions.

Scope & Market Segmentation

  • Disease Types: Alcoholic liver disease, hepatitis B, hepatitis C, liver cancer (including cholangiocarcinoma and hepatocellular carcinoma), and nonalcoholic liver disease.
  • Therapy Types: Biologic immunotherapies, cell-based and regenerative therapies, gene therapy, microbiome-modulating therapies, and small-molecule drugs.
  • Routes of Administration: Intravenous, oral, and subcutaneous options.
  • Drug Classes: Antifibrotic agents (pirfenidone, simtuzumab), antivirals (interferons, NS5A inhibitors, NS5B polymerase inhibitors, nucleotide/nucleoside analogues, protease inhibitors), chemotherapeutics, corticosteroids, immunosuppressants, and monoclonal antibodies.
  • End Users: Clinics, home care settings, hospitals.
  • Distribution Channels: Hospital pharmacies, online pharmacies, retail pharmacies.
  • Regions: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa, and others), Asia-Pacific (China, India, Japan, Australia, South Korea, Indonesia, and more).
  • Key Companies: Gilead Sciences, AbbVie, Merck & Co., Bristol-Myers Squibb, Johnson & Johnson, F. Hoffmann-La Roche, Pfizer, Novartis, GlaxoSmithKline, Intercept Pharmaceuticals by Alfasigma, Sanofi, Takeda, Vertex Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Genfit, Astellas, Moderna, Alnylam Pharmaceuticals.

Key Takeaways for Senior Decision-Makers

  • Pace of innovation in gene editing, cell-based therapies, and microbiome modulation is shifting treatment standards across all liver disease segments.
  • Stakeholders must align their regulatory, clinical, and commercial strategies to match increasingly complex payer requirements and value-based care expectations.
  • Collaboration between pharmaceutical, biotech, academic, and governmental organizations is essential for accelerating pipeline progress and optimizing resource allocation.
  • Regional dynamics shape market access strategies, as regulatory requirements, reimbursement approaches, and technology adoption rates vary widely across continents and countries.
  • Supply chain adjustments and modular manufacturing are gaining significance as market participants address cost volatility and optimize distribution efficiency.
  • Advanced data analytics and digital health tools are now central to therapy development, patient monitoring, and real-world evidence generation.

Tariff Impact: Navigating New Challenges in the United States

Newly implemented United States tariffs on select pharmaceutical ingredients and biomanufactured components are affecting procurement, pricing structures, and supply chain risk management. Companies are exploring nearshoring, dual-sourcing strategies, and collaborative sourcing arrangements to reduce exposure. These adaptations require reevaluation of supply chain models, as well as recalibrated contracts and negotiations with payers to sustainably manage cost pressures and maintain patient access standards.

Methodology & Data Sources

The research methodology integrates extensive secondary research of clinical studies, regulatory documents, and patent landscapes with qualitative insights from industry leaders, clinicians, regulators, and payers. Company financials, partnership activity, and supply chain reports are validated through data triangulation and expert review sessions to ensure reliable, actionable intelligence.

Why This Report Matters: Strategic Value for Leaders

  • Enables decision-makers to anticipate market trends, optimize R&D priorities, and align commercial strategies in a data-driven manner.
  • Offers actionable insights into regulatory shifts, payer expectations, and evolving competitive dynamics specific to the liver disease therapeutics market.
  • Equips teams to proactively address tariff impacts, regional heterogeneity, and supply chain risks for improved resilience and growth potential.

Conclusion

The Liver Diseases Therapeutics Market is being reshaped by scientific innovation, regulatory evolution, and changing market requirements. Leaders who leverage these insights will be positioned to drive effective strategies and capture long-term value in this dynamic sector.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Adoption of gene editing therapies for hereditary liver disorders with improving delivery vector safety profiles
5.2. Increasing prevalence of liver diseases drives therapeutic need
5.3. Integration of artificial intelligence platforms in optimizing nonalcoholic steatohepatitis clinical trials
5.4. Emerging regulatory pathways support cell-based therapeutic innovations for liver failure and cirrhosis
5.5. Growth of patient-centric remote monitoring solutions for early detection and management of hepatic complications
5.6. Surging venture capital investments fuel early-stage liver therapeutics
5.7. Collaborations between pharmaceutical companies and biotech firms to accelerate liver fibrosis drug candidate pipelines
5.8. Growth of combination small molecule and biologic therapies for advanced hepatocellular carcinoma
5.9. Government initiatives and public awareness drive early detection of liver diseases
5.10. Development of personalized medicine pipelines using multiomic biomarkers to predict patient responses in NASH trials
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Liver Diseases Therapeutics Market, by Disease Type
8.1. Introduction
8.2. Alcoholic Liver Disease
8.3. Hepatitis B
8.4. Hepatitis C
8.5. Liver Cancer
8.5.1. Cholangiocarcinoma
8.5.2. Hepatocellular Carcinoma
8.6. Non Alcoholic Lever Disease
9. Liver Diseases Therapeutics Market, by Therapy Type
9.1. Introduction
9.2. Biologic Immunotherapies
9.3. Cell-Based & Regenerative Therapy
9.4. Gene Therapy
9.5. Microbiome-Modulating Therapies
9.6. Small-Molecule Drugs
10. Liver Diseases Therapeutics Market, by Route Of Administration
10.1. Introduction
10.2. Intravenous
10.3. Oral
10.4. Subcutaneous
11. Liver Diseases Therapeutics Market, by Drug Class
11.1. Introduction
11.2. Antifibrotic
11.2.1. Pirfenidone
11.2.2. Simtuzumab
11.3. Antivirals
11.3.1. Interferons
11.3.2. NS5A Inhibitors
11.3.3. NS5B Polymerase Inhibitors
11.3.4. Nucleotide/Nucleoside Analogues
11.3.5. Protease Inhibitors
11.4. Chemotherapeutic
11.5. Corticosteroids
11.6. Immunosuppressants
11.7. Monoclonal Antibody
12. Liver Diseases Therapeutics Market, by End User
12.1. Introduction
12.2. Clinic
12.3. Home Care Settings
12.4. Hospital
13. Liver Diseases Therapeutics Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacy
13.3. Online Pharmacy
13.4. Retail Pharmacy
14. Americas Liver Diseases Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Liver Diseases Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Liver Diseases Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. Gilead Sciences, Inc.
17.3.2. AbbVie Inc.
17.3.3. Merck & Co., Inc.
17.3.4. Bristol-Myers Squibb Company
17.3.5. Johnson & Johnson Services Inc.
17.3.6. F. Hoffmann-La Roche Ltd.
17.3.7. Pfizer Inc.
17.3.8. Novartis AG
17.3.9. GlaxoSmithKline plc
17.3.10. Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
17.3.11. Sanofi SA
17.3.12. Takeda Pharmaceutical Company Limited
17.3.13. Vertex Pharmaceuticals Incorporated
17.3.14. AstraZeneca PLC
17.3.15. C. H. Boehringer Sohn AG & Co. KG
17.3.16. Eli Lilly and Company
17.3.17. Genfit S.A.
17.3.18. Astellas Pharma Inc.
17.3.19. Moderna, Inc.
17.3.20. Alnylam Pharmaceuticals, Inc.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. LIVER DISEASES THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. LIVER DISEASES THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. LIVER DISEASES THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 27. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHAI
FIGURE 28. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHSTATISTICS
FIGURE 29. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHCONTACTS
FIGURE 30. LIVER DISEASES THERAPEUTICS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. LIVER DISEASES THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ALCOHOLIC LIVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS B, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATITIS C, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHOLANGIOCARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HEPATOCELLULAR CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NON ALCOHOLIC LEVER DISEASE, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY BIOLOGIC IMMUNOTHERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CELL-BASED & REGENERATIVE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MICROBIOME-MODULATING THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SMALL-MOLECULE DRUGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PIRFENIDONE, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY SIMTUZUMAB, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5A INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NS5B POLYMERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE/NUCLEOSIDE ANALOGUES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CHEMOTHERAPEUTIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODY, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 113. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 114. AMERICAS LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES LIVER DISEASES THERAPEUTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 135. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 136. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 137. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 138. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 139. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 140. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 141. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 144. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 145. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 146. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 147. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 148. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 149. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 150. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 151. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 152. CANADA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 153. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 154. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 155. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 156. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 157. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 158. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 159. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 160. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 161. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 164. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 165. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. MEXICO LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 172. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 173. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 174. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 175. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 176. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 177. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 178. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 179. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 180. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 189. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 190. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 191. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 192. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 193. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 194. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 195. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 198. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 199. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 200. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 201. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 202. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 208. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 209. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 210. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 211. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 212. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 213. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 216. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 217. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 218. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 219. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 220. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 221. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 222. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 223. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 224. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 227. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 228. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 230. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 232. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 234. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 236. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 238. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 239. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 240. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 241. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 242. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 243. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 244. UNITED KINGDOM LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 245. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 246. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 247. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 248. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 249. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 250. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 251. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 252. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 253. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 254. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 255. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 256. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 257. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 258. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 259. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 262. GERMANY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 263. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 264. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 265. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 266. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 267. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 268. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 269. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 272. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 273. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 274. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 275. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 276. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 277. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. FRANCE LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 282. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 283. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 284. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 285. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 286. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 287. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 288. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 289. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 290. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 291. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2018-2024 (USD MILLION)
TABLE 292. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIFIBROTIC, 2025-2030 (USD MILLION)
TABLE 293. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2018-2024 (USD MILLION)
TABLE 294. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, 2025-2030 (USD MILLION)
TABLE 295. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 298. RUSSIA LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 299. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
TABLE 300. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
TABLE 301. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2018-2024 (USD MILLION)
TABLE 302. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY LIVER CANCER, 2025-2030 (USD MILLION)
TABLE 303. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 304. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 305. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 306. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 307. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 308. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 309. ITALY LIVER DISEASES THERAPEUTICS MARKET SIZE, BY ANTIF

Samples

Loading
LOADING...

Companies Mentioned

  • Gilead Sciences, Inc.
  • AbbVie Inc.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson Services Inc.
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Novartis AG
  • GlaxoSmithKline plc
  • Intercept Pharmaceuticals, Inc. by Alfasigma S.p.A.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Vertex Pharmaceuticals Incorporated
  • AstraZeneca PLC
  • C. H. Boehringer Sohn AG & Co. KG
  • Eli Lilly and Company
  • Genfit S.A.
  • Astellas Pharma Inc.
  • Moderna, Inc.
  • Alnylam Pharmaceuticals, Inc.

Table Information

Report AttributeDetails
No. of Pages192
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 20.26 Billion
Forecasted Market Value ( USD ) by 2030 $ 30 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Liver Fibrosis Drugs Market by Drug Class (Biologic Therapies, Cell Therapies, Gene Therapies), Mechanism Of Action (ASK1 Inhibitors, Galectin-3 Inhibitors, PPAR Agonists), Route Of Administration, Distribution Channel - Global Forecast 2025-2030 - Product Image

Liver Fibrosis Drugs Market by Drug Class (Biologic Therapies, Cell Therapies, Gene Therapies), Mechanism Of Action (ASK1 Inhibitors, Galectin-3 Inhibitors, PPAR Agonists), Route Of Administration, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Liver Cirrhosis - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Liver Cirrhosis - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Product (Antiviral Drugs, Vaccines, Chemotherapy), By Disease (Hepatitis, Autoimmune Diseases), By Region, And Segment Forecasts, 2025 - 2033 - Product Image

Liver Disease Therapeutics Market Size, Share & Trends Analysis Report By Product (Antiviral Drugs, Vaccines, Chemotherapy), By Disease (Hepatitis, Autoimmune Diseases), By Region, And Segment Forecasts, 2025 - 2033

  • Report
  • 150 Pages
  • Global
From
Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Liver Fibrosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 185 Pages
  • Global
From
Liver Metastases Treatment Market by End User (Ambulatory Care Centers, Hospitals, Specialty Clinics), Route of Administration (Intravenous, Oral), Product Type, Treatment Type, Line of Therapy, Primary Tumor Origin, Distribution Channel - Global Forecast 2025-2030 - Product Image

Liver Metastases Treatment Market by End User (Ambulatory Care Centers, Hospitals, Specialty Clinics), Route of Administration (Intravenous, Oral), Product Type, Treatment Type, Line of Therapy, Primary Tumor Origin, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.